REVB
NASDAQRevelation Biosciences Inc.
Revelation Biosciences Inc. (REVB) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for REVB, including 2 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Net income, TTM
- -$12.16M
- Cash
- $9.12M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks23+200%
2026-05-172026-11-08
Mix1290d
- Insider5(42%)
- Other3(25%)
- SEC Filings3(25%)
- Earnings1(8%)
Activity · 52 weeks6840 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- PRRevelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026. Corporate Highlights Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini Announced that it has selected a full-service contract research organization (CRO) with global operations to serve as the CRO for our upcoming study for evaluating Gemini in patients with acute kidney injury (AKI) "The Revelation team remains focused on progressing
- SECSEC Form 10-Q filed by Revelation Biosciences Inc.10-Q - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- PRRevelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L887. The reverse stock split is intended to increase the market price per share o
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- PRRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study– Study on track to begin later this year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). The importance of hiring the right CRO is a critical step for a successful study. The CRO manages the nuts and bolts of running the study including such things as site identification and management, patient
- INSIDERChief Financial Officer Zygmont Chester Stanley Iii was granted 208,073 shares, gifted 208,073 shares and received a gift of 208,073 shares (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Chawla Lakhmir S was granted 32,011 shares, increasing direct ownership by 263% to 44,169 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Roper Jess was granted 32,011 shares, increasing direct ownership by 250% to 44,839 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERChief Executive Officer Rolke James was granted 208,076 shares, increasing direct ownership by 97% to 422,814 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERDirector Carver Jennifer was granted 32,011 shares, increasing direct ownership by 251% to 44,769 units (SEC Form 4)4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.SCHEDULE 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026.Corporate HighlightsAnnounced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory BoardContinued progress on Phase 2/3 clinical study start up activitiesReleased results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini"Start-up act
- SECSEC Form 10-Q filed by Revelation Biosciences Inc.10-Q - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSIndependent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney InjurySAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today results of an independent market assessment which identified a potential $94 billion total addressable market for Gemini, confirming the unmet medical need.The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more than 10% of all hospitalized patients and more than 50% of patients admitted
- NEWSRevelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that on July 15, 2026, the Compensation Committee of Revelation's Board of Directors approved three inducement grants totaling 108,000 restricted stock units ("RSUs") covering 108,000 shares of the Company's common stock to three newly hired non-executive employees. The inducement grants were granted pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan ("2026 Inducement Plan"). The awards were granted as a material inducement t
- SECSEC Form 8-A12B filed by Revelation Biosciences Inc.8-A12B - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Announces Adoption of Stockholder Rights PlanSAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the "Board") has adopted a stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right (a "Right") for each outstanding share of the Company's common stock.The Rights Plan was adopted pursuant to a Rights Agreement, dated as of July 10, 2026 (the "Rights Agreement"), between the Company and Continental Stock Transfer & Trust Company, as rights agent. The dividend is payable to stockhol
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Expands Acute Kidney Injury Advisory BoardSAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress, and advance Gemini as a treatment for AKI. Drawing on their collective expertise, the boa
- SECSEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.SCHEDULE 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECSEC Form DEF 14A filed by Revelation Biosciences Inc.DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
REVB FAQ
10 questionsWhat does Revelation Biosciences Inc. do?
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator...What is the latest news on REVB?
In the last 30 days Quantisnow tracked 4 wire items for REVB: 2 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published on November 5, 2026.Is REVB profitable?
No. Revelation Biosciences Inc. reported a net loss of $12.16M for the twelve months ended Sep 30, 2026.How much cash and debt does REVB have?
Revelation Biosciences Inc. reported $9.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does REVB stock trade?
Revelation Biosciences Inc. (REVB) is listed on NASDAQ.What sector and industry is REVB in?
Revelation Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Revelation Biosciences Inc. go public?
Revelation Biosciences Inc. (REVB) completed its IPO in 2020.What are analysts saying about REVB?
Revelation Biosciences Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $12.00 price target on 2022-02-17. Recent price targets cluster around $12.00.What companies are similar to REVB?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare REVB side-by-side with any of them on Quantisnow.How can I track REVB on Quantisnow?
Quantisnow aggregates Revelation Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REVB to receive live email and push alerts on every new disclosure.